Literature DB >> 25429762

Integrated omic analysis of lung cancer reveals metabolism proteome signatures with prognostic impact.

Lei Li1, Yuhong Wei1, Christine To2, Chang-Qi Zhu2, Jiefei Tong1, Nhu-An Pham2, Paul Taylor1, Vladimir Ignatchenko2, Alex Ignatchenko2, Wen Zhang3, Dennis Wang2, Naoki Yanagawa2, Ming Li2, Melania Pintilie4, Geoffrey Liu5, Lakshmi Muthuswamy6, Frances A Shepherd7, Ming Sound Tsao8, Thomas Kislinger5, Michael F Moran9.   

Abstract

Cancer results from processes prone to selective pressure and dysregulation acting along the sequence-to-phenotype continuum DNA → RNA → protein → disease. However, the extent to which cancer is a manifestation of the proteome is unknown. Here we present an integrated omic map representing non-small cell lung carcinoma. Dysregulated proteins not previously implicated as cancer drivers are encoded throughout the genome including, but not limited to, regions of recurrent DNA amplification/deletion. Clustering reveals signatures composed of metabolism proteins particularly highly recapitulated between patient-matched primary and xenograft tumours. Interrogation of The Cancer Genome Atlas reveals cohorts of patients with lung and other cancers that have DNA alterations in genes encoding the signatures, and this was accompanied by differences in survival. The recognition of genome and proteome alterations as related products of selective pressure driving the disease phenotype may be a general approach to uncover and group together cryptic, polygenic disease drivers.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25429762     DOI: 10.1038/ncomms6469

Source DB:  PubMed          Journal:  Nat Commun        ISSN: 2041-1723            Impact factor:   14.919


  39 in total

1.  Proteomic Interrogation in Cancer Biomarker.

Authors:  Un-Beom Kang
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  Identification and Characterization of Potential Biomarkers by Quantitative Tissue Proteomics of Primary Lung Adenocarcinoma.

Authors:  Chiung-Hung Hsu; Chia-Wei Hsu; Chuen Hsueh; Chih-Liang Wang; Yi-Cheng Wu; Chih-Ching Wu; Chin-Ching Liu; Jau-Song Yu; Yu-Sun Chang; Chia-Jung Yu
Journal:  Mol Cell Proteomics       Date:  2016-05-09       Impact factor: 5.911

3.  Relative protein quantification and accessible biology in lung tumor proteomes from four LC-MS/MS discovery platforms.

Authors:  Paul A Stewart; Bin Fang; Robbert J C Slebos; Guolin Zhang; Adam L Borne; Katherine Fellows; Jamie K Teer; Y Ann Chen; Eric Welsh; Steven A Eschrich; Eric B Haura; John M Koomen
Journal:  Proteomics       Date:  2017-03       Impact factor: 3.984

4.  Ultra-deep tyrosine phosphoproteomics enabled by a phosphotyrosine superbinder.

Authors:  Yangyang Bian; Lei Li; Mingming Dong; Xuguang Liu; Tomonori Kaneko; Kai Cheng; Huadong Liu; Courtney Voss; Xuan Cao; Yan Wang; David Litchfield; Mingliang Ye; Shawn S-C Li; Hanfa Zou
Journal:  Nat Chem Biol       Date:  2016-09-19       Impact factor: 15.040

5.  High FA2H and UGT8 transcript levels predict hydroxylated hexosylceramide accumulation in lung adenocarcinoma.

Authors:  Anne-Marie Lemay; Olivier Courtemanche; Timothy A Couttas; Giuleta Jamsari; Andréanne Gagné; Yohan Bossé; Philippe Joubert; Anthony S Don; David Marsolais
Journal:  J Lipid Res       Date:  2019-08-13       Impact factor: 5.922

6.  Mitofusin-2 over-expresses and leads to dysregulation of cell cycle and cell invasion in lung adenocarcinoma.

Authors:  Yuqing Lou; Rong Li; Jielin Liu; Yanwei Zhang; Xueyan Zhang; Bo Jin; Ya Liu; Zuoguang Wang; Hua Zhong; Shaojun Wen; Baohui Han
Journal:  Med Oncol       Date:  2015-03-22       Impact factor: 3.064

7.  Proteogenomic Analysis of Surgically Resected Lung Adenocarcinoma.

Authors:  Michael F Sharpnack; Nilini Ranbaduge; Arunima Srivastava; Ferdinando Cerciello; Simona G Codreanu; Daniel C Liebler; Celine Mascaux; Wayne O Miles; Robert Morris; Jason E McDermott; James L Sharpnack; Joseph Amann; Christopher A Maher; Raghu Machiraju; Vicki H Wysocki; Ramaswami Govindan; Parag Mallick; Kevin R Coombes; Kun Huang; David P Carbone
Journal:  J Thorac Oncol       Date:  2018-07-11       Impact factor: 15.609

Review 8.  Scalable Signature-Based Molecular Diagnostics Through On-chip Biomarker Profiling Coupled with Machine Learning.

Authors:  John Molinski; Amogha Tadimety; Alison Burklund; John X J Zhang
Journal:  Ann Biomed Eng       Date:  2020-08-20       Impact factor: 3.934

9.  [Value of CHCHD2 as a potential marker of non-small cell lung cancer: analysis of 60 cases].

Authors:  Rui Xu; Sheng-Yu Wang; Li Wang; Man-Xiang Li; Yang Yao
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-03-20

Review 10.  Biomarker development in the precision medicine era: lung cancer as a case study.

Authors:  Ashley J Vargas; Curtis C Harris
Journal:  Nat Rev Cancer       Date:  2016-07-08       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.